Coming soon from SECUADO

SECUADO®, the first and only FDA-approved transdermal system for adults with schizophrenia: IT’S ON

Why transdermal?

When your patients with schizophrenia are ready for a change of treatment, the transdermal patch offers you the opportunity to change the conversation with a different treatment option. The SECUADO® patch is an option for your patients who:

• Are looking for or need a different atypical antipsychotic treatment
• Want an alternative to swallowing pills or receiving injections
• Dislike food or drink restrictions when taking medicine
• Might be candidates for a once-daily treatment they can wear

Transdermal delivery is different

SECUADO® releases medication gradually, for consistent and sustained delivery over 24 hours.1,3 The transdermal route of administration avoids first-pass hepatic metabolism4-6 and has the potential to reduce GI tolerability concerns.4,5,7 Absorption is not impacted by the timing of food or drink.4,7

SECUADO® provided smooth onset, steady delivery, and low peak-to-trough ratios3

Asenapine pharmacokinetics at steady state is dose-proportional in the dose range of 3.8 mg/24 hours to 7.6 mg/24 hours following application of the patch.1 Steady-state plasma concentrations are achieved in about 72 hours after the first application of SECUADO.1

Avoid exposing SECUADO® to direct external heat sources during wear because both the rate and extent of absorption are increased.

    You are now leaving the SECUADO® (asenapine) transdermal system website and moving to an external website independently operated and not managed by Noven

    The site you are about to enter is intended specifically for US healthcare professionals.

    Click continue if you are a US healthcare professional.